Micro- and Nanotechnology in Vaccine Development

1st Edition - September 20, 2016
Editors: Mariusz Skwarczynski, Istvan Toth
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 3 9 9 8 1 - 4
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 4 0 0 2 9 - 9

This book provides a comprehensive overview of how use of micro- and nanotechnology (MNT) has allowed major new advance in vaccine development research, and the challenges that im… Read more

Micro- and Nanotechnology in Vaccine Development

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

This book provides a comprehensive overview of how use of micro- and nanotechnology (MNT) has allowed major new advance in vaccine development research, and the challenges that immunologists face in making further progress.

MNT allows the creation of particles that exploit the inherent ability of the human immune system to recognize small particles such as viruses and toxins. In combination with minimal protective epitope design, this permits the creation of immunogenic particles that stimulate a response against the targeted pathogen. The finely tuned response of the human immune system to small particles makes it unsurprising that many of the lead adjuvants and vaccine delivery systems currently under investigation are based on nanoparticles.

Mariusz Skwarczynski

Mariusz Skwarczynski completed his Ph.D. in Chemistry in 1999 at Wroclaw University of Technology. His postdoctoral training began at Tokushima Bunri University under the direction of Professor M. Nishizawa, where he studied the biomimetic total synthesis of anticancer agent paclitaxel. He then joined the laboratory of Professor Yoshiaki Kiso at Kyoto Pharmaceutical University to study prodrugs of paclitaxel. In 2004 he was awarded with prestigious Japanese fellowship (Japan Society for the Promotion of Science postdoctoral fellowship) and research grant to conduct further research on paclitaxel. He developed novel classes of paclitaxel prodrugs: isotaxoids and phototaxels. He also developed an epimerization-free method for the synthesis of novel building blocks (isodipeptides) for solid phase peptide synthesis and these units have been commercialized by Merck-Novabiochem. In 2008 he joined Professor Istvan Toth group at University of Queensland to work on drug, gene and vaccine delivery strategies. Since then he research is mainly focused on nanotechnology-based vaccine delivery approaches. He has published over 60 peer-reviewed publications, 4 book chapters, and other 100 conference abstracts. Currently he is Vice-Chancellor Fellow at University of Queensland.

Affiliations and expertise

Vice-Chancellor and Fellow, University of Queensland, Australia

Istvan Toth

Professor Toth is a chemical engineer with a research focus on medicinal chemistry. He was awarded his PhD in 1972 and has since worked in Hungary, Canada and the United Kingdom before relocating to Australia in 1998. His major research interests are drug delivery, immunoadjuvants, synthetic vaccines and gene delivery. His research has attracted over $60 million in competitive grants, research contracts and investment funds in the past 10 years. He has over 300 peer-reviewed publications, 43 patents, and an excellent track record in research commercialization as a key founder of Alchemia (ASX listed), Implicit Bioscience Pty Ltd, Neurotide Pty Ltd and TetraQ (the commercial arm of Centre of Integrated Preclinical Drug Development).

Affiliations and expertise

ARC Australian Professorial Fellow, Chair in Biological Chemistry, Professor of Pharmacy, Group Leader, IMB Division of Structural Biology